501684-29-3

Basic information

• Product Name: 3-Quinolinecarbonitrile, 4-[(3-chloro-4-fluorophenyl)amino]-7-(3-chloropropoxy)-6-nitro-
• CAS NO: 501684-29-3
• Molecular Formula: C19H13Cl2FN4O3
• Molecular Weight: 435.242
• Mol File: 501684-29-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 3-Quinolinecarbonitrile, 4-[(3-chloro-4-fluorophenyl)amino]-7-(3-chloropropoxy)-6-nitro-(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Quinolinecarbonitrile, 4-[(3-chloro-4-fluorophenyl)amino]-7-(3-chloropropoxy)-6-nitro-(501684-29-3)
• EPA Substance Registry System: 3-Quinolinecarbonitrile, 4-[(3-chloro-4-fluorophenyl)amino]-7-(3-chloropropoxy)-6-nitro-(501684-29-3)

Safety Data

• Hazardous Substances Data: 501684-29-3(Hazardous Substances Data)

Upstream product

• 501684-27-1 7-(3-chloro-propoxy)-4-hydroxy-6-nitroquinoline-3-carbonitrile 
• 501684-26-0 (E)-2-Cyano-3-(3-methoxy-4-nitro-phenylamino)-acrylic acid ethyl ester 
• 214470-27-6 7-methoxy-4-hydroxy-6-nitroquinoline-3-carbonitrile 
• 536-90-3 m-Anisidine 
• 367-21-5 3-chloro-4-fluorophenylamine 
• 501684-28-2 4-chloro-7-(3-chloropropoxy)-6-nitroquinoline-3-carbonitrile 

Downstream Products

• 501684-31-7 6-amino-4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinoline-3-carbonitrile 
• 501684-30-6 4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-6-nitro-quinoline-3-carbonitrile 

Relevant articles and documents

Syntheses and EGFR and HER-2 kinase inhibitory activities of 4-anilinoquinoline-3-carbonitriles: Analogues of three important 4-anilinoquinazolines currently undergoing clinical evaluation as therapeutic antitumor agents

The syntheses and biological evaluations of 4-anilinoquinoline-3-carbonitrile analogues of the three clinical lead 4-anilinoquinazolines Iressa, Tarceva, and CI-1033 are described. The EGFR and HER-2 kinase inhibitory activities and the cell growth inhibition of the two series are compared with each other and with the clinical lead EKB-569. Similar activities are observed between these two series.